Zivo Bioscience, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Zivo Bioscience, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $157.2K | Mar 18, 2025 |
| FY2024 | Dec 31, 2023 | $27.7K | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $20.0K | Apr 22, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $0 | Mar 26, 2020 |
| FY2016 | Dec 31, 2016 | $0 | Mar 31, 2017 |
| FY2016 | Dec 31, 2015 | $0 | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $0 | Mar 29, 2016 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $157.2K | Mar 18, 2025 |
| FY2024 | Dec 31, 2023 | $27.7K | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Mar 15, 2024 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Dec 31, 2012 | $0 | Mar 25, 2013 |
| FY2011 | Dec 31, 2011 | $88.9K | Mar 30, 2012 |
| FY2011 | Dec 31, 2010 | $77.7K | Mar 30, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $49.0K | Mar 18, 2025 |
| FY2024 | Dec 31, 2023 | $11.6K | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Mar 15, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($13.38M) | Mar 18, 2025 |
| FY2024 | Dec 31, 2023 | ($7.78M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($8.75M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($8.76M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($9.11M) | Apr 22, 2022 |
| FY2020 | Dec 31, 2019 | ($11.51M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($14.64M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($10.04M) | Feb 12, 2019 |
| FY2016 | Dec 31, 2016 | ($6.06M) | Mar 31, 2017 |
| FY2016 | Dec 31, 2015 | ($5.79M) | Mar 31, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($13.36M) | Mar 18, 2025 |
| FY2024 | Dec 31, 2023 | ($7.26M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($8.73M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($8.65M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($8.56M) | Apr 22, 2022 |
| FY2020 | Dec 31, 2019 | ($8.35M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($6.13M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($6.33M) | Feb 12, 2019 |
| FY2016 | Dec 31, 2016 | ($3.49M) | Mar 31, 2017 |
| FY2016 | Dec 31, 2015 | ($3.06M) | Mar 31, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $3.13M | Mar 18, 2025 |
| FY2024 | Dec 31, 2023 | $1.38M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $2.24M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $1.95M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $3.75M | Apr 22, 2022 |
| FY2020 | Dec 31, 2019 | $2.31M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $2.81M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $2.38M | Feb 12, 2019 |
| FY2016 | Dec 31, 2016 | $789.0K | Mar 31, 2017 |
| FY2016 | Dec 31, 2015 | $1.03M | Mar 31, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($4.31M) | Mar 18, 2025 |
| FY2024 | Dec 31, 2023 | ($5.80M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($7.10M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($6.80M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($2.59M) | Apr 22, 2022 |
| FY2020 | Dec 31, 2019 | ($3.71M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($5.01M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($4.24M) | Feb 12, 2019 |
| FY2016 | Dec 31, 2016 | ($2.54M) | Mar 31, 2017 |
| FY2016 | Dec 31, 2015 | ($2.30M) | Mar 31, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $0 | Mar 31, 2014 |
| FY2013 | Dec 31, 2012 | ($3.5K) | Mar 31, 2014 |
| FY2011 | Dec 31, 2011 | ($4.7K) | Mar 30, 2012 |
| FY2011 | Dec 31, 2010 | ($29.6K) | Mar 30, 2012 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.64M | Mar 18, 2025 |
| FY2024 | Dec 31, 2023 | $555.7K | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $2.12M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $8.99M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $220.2K | Apr 22, 2022 |
| FY2020 | Dec 31, 2019 | $369.4K | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $411.5K | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $332.3K | Feb 12, 2019 |
| FY2016 | Dec 31, 2016 | $737.3K | Mar 31, 2017 |
| FY2016 | Dec 31, 2015 | $72.7K | Mar 31, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $2.16M | Mar 18, 2025 |
| FY2024 | Dec 31, 2023 | $2.76M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $2.13M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $2.95M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $11.53M | Apr 22, 2022 |
| FY2020 | Dec 31, 2019 | $8.71M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $22.69M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $16.64M | Feb 12, 2019 |
| FY2016 | Dec 31, 2016 | $14.36M | Mar 31, 2017 |
| FY2016 | Dec 31, 2015 | $9.57M | Mar 31, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($514.9K) | Mar 18, 2025 |
| FY2024 | Dec 31, 2023 | ($2.21M) | Mar 18, 2025 |
| FY2024 | Dec 31, 2022 | ($10.6K) | Mar 18, 2025 |
| FY2023 | Dec 31, 2021 | $6.04M | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | ($11.31M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2019 | ($8.34M) | Apr 22, 2022 |
| FY2019 | Dec 31, 2018 | ($22.28M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($16.30M) | Feb 12, 2019 |
| FY2016 | Dec 31, 2016 | ($13.62M) | Mar 31, 2017 |
| FY2016 | Dec 31, 2015 | ($9.50M) | Mar 31, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($136.97M) | Mar 18, 2025 |
| FY2024 | Dec 31, 2023 | ($123.58M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($115.80M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($107.06M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($99.06M) | Apr 22, 2022 |
| FY2020 | Dec 31, 2019 | ($89.96M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($78.45M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($63.81M) | Feb 12, 2019 |
| FY2016 | Dec 31, 2016 | ($53.77M) | Mar 31, 2017 |
| FY2016 | Dec 31, 2015 | ($47.71M) | Mar 31, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $1.80M | Mar 14, 2023 |
| FY2022 | Dec 31, 2021 | $8.90M | Mar 14, 2023 |
| FY2022 | Dec 31, 2020 | $137.9K | Mar 14, 2023 |
| FY2021 | Dec 31, 2019 | $346.1K | Apr 22, 2022 |
| FY2020 | Dec 31, 2018 | $388.9K | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $317.1K | Mar 26, 2020 |
| FY2018 | Dec 31, 2016 | $507.0K | Feb 12, 2019 |
| FY2016 | Dec 31, 2015 | $16.6K | Mar 31, 2017 |
| FY2016 | Jan 1, 2015 | $1.4K | Mar 31, 2017 |
| FY2014 | Dec 31, 2014 | $1.4K | Apr 6, 2015 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (4) | Mar 18, 2025 |
| FY2024 | Dec 31, 2023 | (4) | Mar 18, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 3.62M | Mar 18, 2025 |
| FY2024 | Dec 31, 2023 | 2.38M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | 1.57M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | 9.42M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | 5.16M | Apr 22, 2022 |
| FY2020 | Dec 31, 2019 | 413.04M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 180.04M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | 141.11M | Feb 12, 2019 |
| FY2016 | Dec 31, 2016 | 136.75M | Mar 31, 2017 |
| FY2016 | Dec 31, 2015 | 132.16M | Mar 31, 2017 |